Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362152 | 1.00 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL24513002 | 1.00 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL25630145 | 0.93 | TYMP (0.42) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL24513003 | 0.90 | TYMP (0.40) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL30140997 | 0.87 | TYMP (0.51) | TYMPTAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL23827271 | 0.86 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL22408789 | 0.86 | TYMP (0.48) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19362174 | 0.86 | TYMP (0.48) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19356965 | 0.85 | TYMP (0.44) | TYMPTAS1R3TAS1R1HPGDTAAR1 | |
| SCHEMBL23425438 | 0.85 | KDM4E (0.36) | TYMPKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267843-B2 | Stereodefining L-monomers | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-03-08 | — | — | US | disclosed |
| US-20200291056-A1 | ACYL-PROTECTED L-LNA-GUANOSINE L-MONOMERS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TYMP 19/4885KDM4E 4818/4885TAS1R3 3677/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | TYMP 19/4885KDM4E 4818/4885TAS1R3 3677/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | TYMP 61/4885KDM4E 4758/4885TAS1R3 4005/4885 |
| US-11267843-B2 | Stereodefining L-monomers | RNMT, BCDIN3D, RNGTT | TYMP 51/4885KDM4E 2867/4885TAS1R3 2187/4885 |
| US-20200291056-A1 | ACYL-PROTECTED L-LNA-GUANOSINE L-MONOMERS | GDA, RNMT, RNGTT | TYMP 23/4885KDM4E 4023/4885TAS1R3 4343/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TYMP 19/4885KDM4E 4818/4885TAS1R3 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.